Epic founder among health IT leaders on Forbes richest self-made women list

Judy Faulkner, founder of EHR provider Epic, was recently ranked No. 3 on Forbes’ Richest Self-Made Women 2018.

Epic, which Faulkner started in 1979 in a Wisconsin basement, supports the medical records of more than 230 million patients and touts top medical centers as customers, including Johns Hopkins and Mayo Clinic, according to Forbes. The company totaled $2.7 billion in sales in 2017.

With a net worth of $3.5 billion, Faulkner is one of a few women in the health IT field to make Forbes’ list.

Forbes, which named 60 women in total on its list, compiles net worth with individual assets, including stakes in public companies and consulting with outside experts to compare private company values. Women had to have made their fortunes mostly in the U.S. and be U.S. citizens or permanent residents.

Here are the other women in health and related fields who made the list and their ranking:

11. Thai Lee, CEO of IT provider SHI International
19. Alice Schwartz, founder of Bio-Rad Laboratories
32. Safra Catz, co-CEO of Oracle
44. Anne Wojcicki, founder and CEO of 23andme
57. Martine Rothblatt, founder of United Therapeutics

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.